Are the French and German P&MA systems heading in the same direction?
Defining a robust pricing and market access (P&MA) strategy is indispensable for companies aiming for a successful launch in Europe. France and Germany stand out as key European markets demanding strategic attention due to their significant market size, stringent Health Technology Assessment (HTA) requirements, economic impact, and integral role in international price referencing.
Understanding their healthcare models and converging P&MA developments is a key agenda item for the global summit of pharmaceutical stakeholders. As recent healthcare reforms shape the landscapes of France and Germany, we answer the question: Are the French and German P&MA systems heading toward the same destination? We explore the parallels in their current healthcare models, observe evolving dynamics, and dissect the future course of pharmaceutical success in these influential European markets.
